Drug treatments for schizophrenia - Past, present and future

International Journal of Psychiatry in Clinical Practice

Volumn 1, Issue 4, 1997, Pages 227-230

  Rasmussen, Jill G C ^a  

^a Leacroft Medical Practice   (United Kingdom)

Author keywords

Atypical antipsychotics; Olanzapine; Quetiapine; Risperidone; Sertindole; Typical antipsychotics; Ziprasidone

Indexed keywords

EID: 0345163409     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.3109/13651509709024733     Document Type: Article

References (24)

1. Jablensky A, Sartorius N, Emberg G et al (1992) Schizophrenia manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med (Monograph Suppl) 20: 1-97.
2. Bilder RM, Lipschutz-Broch L, Reifer G (1992) Intellectual deficits in first episode schizophrenia: evidence for progressive deterioration. Schizophrenia Bull 18: 437-448.
3. Kissling W (ed) (1991) The current unsatisfactory response of relapse prevention in schizophrenic psychoses. Clin Neuropathol 2 (suppl. 14): 533-544.
4. Gaebel W, Pietzcker A (1985) One year outcome of schizophrenic patients - the interaction of chronicity and neuroleptic treatment. Pharmacopsychiatry 18: 235-239.
5. Pickar D (1995) Prospects for pharmacotherapy of schizophrenia. Lancet 345: 557-562.
6. Baldessarini RJ, Frankenburg FR (1991) Clozapine: a novel antipsychotic agent. N Engl J Med 324: 746-754.
7. Krupp P, Barnes P (1992) Clozapine-associated agranulocytosis; risk and aetiology. Br J Psychiatry 160 (suppl. 17): 38-40.
8. Meltzer HY (1989) Clinical studies in the mechanism of action of clozapine: the dopamine-serotonin. Psychopharmacol 99: S18-S27.
9. 2 receptor blocking agent. Curr Ther Res 40: 492-499.
10. Leysen JE, Janssen PMF, Gommeren W et al (1992) In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol Pharmacol 41: 494-508.
11. Pseukens J, on behalf of the Risperidone Study Group. (1995) Risperidone in the treatment of chronic schizophrenic patients: a multinational, multicentre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 166: 712-726.
12. Marder SR, Meibach RC (1994) Risperidone in the treatment of schizophrenia. Am J Psychiatry 151,6: 825-835.
13. Mertens C (1991) Long-term treatment of chronic schizophrenic patients with risperidone. In: Risperidone: Major progress in antipsychotic treatment (ed. Kane JM) 44-48. Oxford: Oxford Clinical Communications.
14. Wirsching W, Ames D, Marder SR et al (1996) Risperidone in treatment resistant schizophrenia. Abstract S-1115-3 presented at World Congress of Psychiatry, Madrid.
15. Kopala L (1996) The optimal dose of risperidone. Abstract S-145-5, presented at World Congress of Psychiatry, Madrid.
16. Goldstein JM (1995) Pre-clinical pharmacology of new atypical antipsychotics in late stage development. Exp Opin Invest Drugs 4: 50-73.
17. Tollefson GD, Beasley CM, Tran PV et al (1997) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. Am J Psychiatry 154, 4: 457-465.
18. Casey DE (1996) Side effect profiles of New Antipsychotic Agents. J Clin Psych 57(suppl. 11): 40-45.
19. Borison RL (1995) Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. J Clin Psychopharmacol 15: 24S-29S.
20. Targum S, Zborowski J, Henry M et al (1995) Efficacy and safety of sertindole in two double-blind, placebo-controlled trials of schizophrenic patients. Eur Neuropsychopharmacol 5: 348-349.
21. Garson A (1993) How to measure the QT interval - What is normal? Am J Cardiology 72: 14B-16B.
22. Hammer M, Arvanitis L, Miller BG et al (1996) Plasma prolactin in schizophrenia subjects treated with Seroquel™ (ICI 204,636). Psychopharmacology Bulletin 32(1): 107-110.
23. Kalali AH, Potkin SG (1996) University of California, USA. Patient's satisfaction with and acceptibility of 'Seroquel' (ICI 204,636) Eur Neuropsychopharmacol 6(suppl 3). Abstracts of the 20th Collegium Internationale Neuropsychopharmacologicum Congress, Melbourne, 23-27 June.
24. O'Connor R, Harrigan E, Heym J et al (1996) The efficacy and safety profile of a new antipsychotic, ziprasidone. Poster 92 presented at ACNP, Puerto Rico, December, 1996.